FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Hiroshi Maruta

Research Profile

Anatomy

3T3 Cells

Living Beings

Chemicals & Drugs

Disorders

Cell Transformation, Neoplastic

Physiology

Concepts & Ideas

Molecular Sequence Data

Genes & Molecular Sequences

Co-author Network

Publications

TOP 3
Yumiko Hirokawa; Alexander Levitzki; Guillaume Lessene; Jonathan Baell; Yi Xiao; Hongjian Zhu; Hiroshi Maruta
Signal therapy of human pancreatic cancer and NF1-deficient breast cancer xenograft in mice by a combination of PP1 and GL-2003, anti-PAK1 drugs (Tyr-kinase inhibitors).
Yumiko Hirokawa; Thao Nheu; Kirsten Grimm; Victor Mautner; Satoko Maeda; Minoru Yoshida; Kanki Komiyama; Hiroshi Maruta
Sichuan pepper extracts block the PAK1/cyclin D1 pathway and the growth of NF1-deficient cancer xenograft in mice.
Yumiko Hirokawa; Melissa Arnold; Hidenori Nakajima; John Zalcberg; Hiroshi Maruta
Signal therapy of breast cancers by the HDAC inhibitor FK228 that blocks the activation of PAK1 and abrogates the tamoxifen-resistance.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Hiroshi Maruta (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2007: Yumiko Hirokawa; Alexander Levitzki; Guillaume Lessene; Jonathan Baell; Yi Xiao; Hongjian Zhu; Hiroshi Maruta
Signal therapy of human pancreatic cancer and NF1-deficient breast cancer xenograft in mice by a combination of PP1 and GL-2003, anti-PAK1 drugs (Tyr-kinase inhibitors).
Cancer letters 2007;245(1-2):242-51.
2006: Yumiko Hirokawa; Thao Nheu; Kirsten Grimm; Victor Mautner; Satoko Maeda; Minoru Yoshida; Kanki Komiyama; Hiroshi Maruta
Sichuan pepper extracts block the PAK1/cyclin D1 pathway and the growth of NF1-deficient cancer xenograft in mice.
Cancer biology & therapy 2006;5(3):305-9.
2005: Yumiko Hirokawa; Melissa Arnold; Hidenori Nakajima; John Zalcberg; Hiroshi Maruta
Signal therapy of breast cancers by the HDAC inhibitor FK228 that blocks the activation of PAK1 and abrogates the tamoxifen-resistance.
Cancer biology & therapy 2005;4(9):956-60.
2005: Yumiko Hirokawa; Hidenori Nakajima; C Oliver Hanemann; Andreas Kurtz; Silke Frahm; Victor Mautner; Hiroshi Maruta
Signal therapy of NF1-deficient tumor xenograft in mice by the anti-PAK1 drug FK228.
Cancer biology & therapy 2005;4(4):379-81.
2004: Yumiko Hirokawa; Anjali Tikoo; John Huynh; Tamara Utermark; C Oliver Hanemann; Marco Giovannini; Guang-Hui Xiao; Joseph R Testa; John Wood; Hiroshi Maruta
A clue to the therapy of neurofibromatosis type 2: NF2/merlin is a PAK1 inhibitor.
Cancer journal (Sudbury, Mass.) 2004;10(1):20-6.
2004: Hong He; Yumiko Hirokawa; Aviv Gazit; Yoshihiro Yamashita; Hiroyuki Mano; Yuko Kawakami; Ching-Yi Hsieh; Hsing-Jien Kung; Guillaume Lessene; Jonathan Baell; Alexander Levitzki; Hiroshi Maruta
The Tyr-kinase inhibitor AG879, that blocks the ETK-PAK1 interaction, suppresses the RAS-induced PAK1 activation and malignant transformation.
Cancer biology & therapy 2004;3(1):96-101.
2004: Thao Nheu; Hong He; Yumiko Hirokawa; Francesca Walker; John Wood; Hiroshi Maruta
PAK is essential for RAS-induced upregulation of cyclin D1 during the G1 to S transition.
Cell cycle (Georgetown, Tex.) 2004;3(1):71-4.
2003: Hiroshi Maruta; Thao Nheu; Hong He; Yumiko Hirokawa
Rho family-associated kinases PAK1 and rock.
Progress in cell cycle research 2003;5():203-10.
2002: Thao Nheu; Hong He; Yumiko Hirokawa; Kazuhiko Tamaki; Lore Florin; M Lienhard Schmitz; Ikuko Suzuki-Takahashi; Robert N Jorissen; Antony W Burgess; Susumu Nishimura; John Wood; Hiroshi Maruta
The K252a derivatives, inhibitors for the PAK/MLK kinase family selectively block the growth of RAS transformants.
Cancer journal (Sudbury, Mass.) 2002;8(4):328-36.
2002: Hiroshi Maruta; Hong He; Thao Nheu
Interfering with Ras signaling using membrane-permeable peptides or drugs.
Methods in molecular biology (Clifton, N.J.) 2002;189():75-85.
2001: H He; Alexander Levitzki; Hong-Jian Zhu; Francesca Walker; A Burgess; Hiroshi Maruta
Platelet-derived growth factor requires epidermal growth factor receptor to activate p21-activated kinase family kinases.
The Journal of biological chemistry 2001;276(29):26741-4.
2001: Pallavi Sachdev; Y X Jiang; Weiqun Li; Toru Miki; Hiroshi Maruta; MS Nur-E-Kamal; Lu-Hai Wang
Differential requirement for Rho family GTPases in an oncogenic insulin-like growth factor-I receptor-induced cell transformation.
The Journal of biological chemistry 2001;276(28):26461-71.
2001: Kazuhiko Tamaki; J Brad Shotwell; Ryan D White; Ioana Drutu; D T Petsch; Thao Nheu; Hong He; Yumiko Hirokawa; Hiroshi Maruta; John L Wood
Efficient syntheses of novel C2'-alkylated (+/-)-K252a analogues.
Organic letters 2001;3(11):1689-92.
2001: H He; Yumiko Hirokawa; E Manser; L Lim; A Levitzki; Hiroshi Maruta
Signal therapy for RAS-induced cancers in combination of AG 879 and PP1, specific inhibitors for ErbB2 and Src family kinases, that block PAK activation.
Cancer journal (Sudbury, Mass.) 2001;7(3):191-202.
2001: Jun Zeng; Thao Nheu; Anna Zorzet; Bruno Catimel; Edouard C Nice; Hiroshi Maruta; Antony W Burgess; Herbert Treutlein
Design of inhibitors of Ras--Raf interaction using a computational combinatorial algorithm.
Protein engineering 2001;14(1):39-45.
2000: Anjali Tikoo; Suzanne Czekay; Carrie Viars; S White; Joan K Heath; Karen C Arden; Hiroshi Maruta
p190-A, a human tumor suppressor gene, maps to the chromosomal region 19q13.3 that is reportedly deleted in some gliomas.
Gene 2000;257(1):23-31.
2000: M Fridman; Hiroshi Maruta; J Gonez; Francesca Walker; Herbert Treutlein; Jun Zeng; A Burgess
Point mutants of c-raf-1 RBD with elevated binding to v-Ha-Ras.
The Journal of biological chemistry 2000;275(39):30363-71.
2000: H He; Yumiko Hirokawa; A Levitzki; Hiroshi Maruta
An anti-Ras cancer potential of PP1, an inhibitor specific for Src family kinases: in vitro and in vivo studies.
Cancer journal (Sudbury, Mass.) 2000;6(4):243-8.
2000: Anjali Tikoo; R Shakri; L Connolly; Yumiko Hirokawa; T Shishido; B Bowers; Li-Hong Ye; K Kohama; R J Simpson; Hiroshi Maruta
Treatment of ras-induced cancers by the F-actin-bundling drug MKT-077.
Cancer journal (Sudbury, Mass.) 2000;6(3):162-8.
1999: MS Nur-E-Kamal; J M Kamal; MM Qureshi; Hiroshi Maruta
The CDC42-specific inhibitor derived from ACK-1 blocks v-Ha-Ras-induced transformation.
Oncogene 1999;18(54):7787-93.
1999: Hiroshi Maruta; H He; Anjali Tikoo; T Vuong; MS Nur-E-Kamal
G proteins, phosphoinositides, and actin-cytoskeleton in the control of cancer growth.
Microscopy research and technique 1999;47(1):61-6.
1999: Anjali Tikoo; H Cutler; Su Hao Lo; L B Chen; Hiroshi Maruta
Treatment of Ras-induced cancers by the F-actin cappers tensin and chaetoglobosin K, in combination with the caspase-1 inhibitor N1445.
The cancer journal from Scientific American 1999;5(5):293-300.
1999: MS Nur-E-Kamal; MM Qureshi; J M Kamal; W Montague; Hiroshi Maruta
Construction of a cell-permeable CDC42 binding fragment of ACK that inhibits v-Ha-Ras transformation.
Annals of the New York Academy of Sciences 1999;886():285-8.
1999: Hiroshi Maruta; Anjali Tikoo; R Shakri; T Shishido
The anti-RAS cancer drug MKT-077 is an F-actin cross-linker.
Annals of the New York Academy of Sciences 1999;886():283-4.
1999: Hiroshi Maruta; H He; Anjali Tikoo; MS Nur-E-Kamal
Cytoskeletal tumor suppressors that block oncogenic RAS signaling.
Annals of the New York Academy of Sciences 1999;886():48-57.
1999: Jun Zeng; M Fridman; Hiroshi Maruta; Herbert Treutlein; T Simonson
Protein-protein recognition: an experimental and computational study of the R89K mutation in Raf and its effect on Ras binding.
Protein science : a publication of the Protein Society 1999;8(1):50-64.
1998: H He; T Watanabe; X Zhan; C Huang; E Schuuring; K Fukami; T Takenawa; C C Kumar; R J Simpson; Hiroshi Maruta
Role of phosphatidylinositol 4,5-bisphosphate in Ras/Rac-induced disruption of the cortactin-actomyosin II complex and malignant transformation.
Molecular and cellular biology 1998;18(7):3829-37.
1997: Hiroshi Maruta
[F-actin cappers].
Gan to kagaku ryoho. Cancer & chemotherapy 1997;24(11):1442-7.
1997: Hiroshi Maruta
[NF1 (neurofibromatosis type 1)].
Gan to kagaku ryoho. Cancer & chemotherapy 1997;24(11):1422-6.
1997: Hiroshi Maruta
[In memory of the HeLa cell donor (Hensieta Lacks): contribution of a black lady to the cancer research].
Gan to kagaku ryoho. Cancer & chemotherapy 1997;24(11):1366-7.
1997: D Z Wang; MS Nur-E-Kamal; Anjali Tikoo; W Montague; Hiroshi Maruta
The GTPase and Rho GAP domains of p190, a tumor suppressor protein that binds the M(r) 120,000 Ras GAP, independently function as anti-Ras tumor suppressors.
Cancer research 1997;57(12):2478-84.
1994: M Fridman; Anjali Tikoo; M Varga; A Murphy; MS Nur-E-Kamal; Hiroshi Maruta
The minimal fragments of c-Raf-1 and NF1 that can suppress v-Ha-Ras-induced malignant phenotype.
The Journal of biological chemistry 1994;269(48):30105-8.
1994: Anjali Tikoo; M Varga; Vijaya Ramesh; James Gusella; Hiroshi Maruta
An anti-Ras function of neurofibromatosis type 2 gene product (NF2/Merlin).
The Journal of biological chemistry 1994;269(38):23387-90.
1993: MS Nur-E-Kamal; M Varga; Hiroshi Maruta
The GTPase-activating NF1 fragment of 91 amino acids reverses v-Ha-Ras-induced malignant phenotype.
The Journal of biological chemistry 1993;268(30):22331-7.
1992: M S Nur-E-Kamal; Hiroshi Maruta
The role of Gln61 and Glu63 of Ras GTPases in their activation by NF1 and Ras GAP.
Molecular biology of the cell 1992;3(12):1437-42.